arrow
L

Laurent Peyrin-Biroulet

University of Lorraine
H指数:137
被引数:8.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Persistence, Safety and Pharmacokinetics of Vedolizumab After Switching to the Subcutaneous Route in a Prospective French National Cohort Study

维多利珠单抗转换至皮下给药途径后的持续性、安全性和药代动力学:一项法国前瞻性全国队列研究

2026-09-280
PRE
Integrated metabolomic and genetic profiling implicate loss of docosahexaenoic acid in the link between ultra-processed foods and Crohn’s disease

整合代谢组学和遗传学分析表明,超加工食品与克罗恩病之间的关联涉及二十二碳六烯酸的缺失

2026-09-160
PRE
Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study

克罗恩病患者通过自体注射器接受 risankizumab 维持治疗的接受度和耐受性:ACCEPT-OBI 研究结果

2026-09-100
PRE
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression

溃疡性结肠炎患者术前接受高级疗法后术后并发症的对比风险:一项包含Meta回归的网络Meta分析

2026-08-080
PRE
IOIBD: the International Organization for the Study of Inflammatory Bowel Disease

IOIBD:国际炎症性肠病研究组织

2026-08-020
PRE
Global Roll-Out and Continued Multi-Site Validation of the Artificial Intelligence Histology Instrument for Qualitative Assessment of Histopathology in Ulcerative Colitis

全球推广及人工智能组织学仪器在溃疡性结肠炎组织病理学定性评估中的多中心持续验证

2026-07-300
OAAI
Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments

与生物制剂治疗相比,美国溃疡性结肠炎患者使用托法替布治疗发生严重感染、心肌梗死、中风和血栓栓塞事件的风险

2026-07-280
OAAI
Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study

甲氨蝶呤治疗炎症性肠病:MICI-METHO多中心回顾性队列研究

2026-07-220
PRE
Answer to Elbaz et al.

Elbaz等人的回应

2026-07-060
PRE
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus

是时候重新思考炎症性肠病临床试验中的清洗期:一项国际德尔菲共识

2026-05-010
PRE
Building a Robust Investigator-Initiated Platform: The I-CARE Experience

构建一个稳健的 investigator-initiated 平台:I-CARE 经验

2026-02-150
OAAI